Cannabis and Insomnia: What the Research Shows

8 min read

In a hurry? Scroll to the bottom for a summary.

What you’ll learn in this article

• Why cannabis appears to improve sleep, and what’s actually happening to your brain while it does
• The specific sleep architecture change that makes nightly use a trap over time
• Why stopping cannabis often makes insomnia dramatically worse before it gets better
• Where cannabis genuinely has clinical evidence, and where it doesn’t
• Why one in a thousand people with insomnia receive the first-line recommended treatment

A client I’ll call Dana had been using cannabis to sleep for four years. It worked beautifully at first. Fifteen minutes after a small vape hit, she was out. Then it took two hits. Then a higher-THC product. Then two products. By the time she reached me, she was using cannabis every night, sleeping five fragmented hours, and spending her days in what she described as “a fog that never quite lifts.”

She didn’t have a sleep problem anymore. She had two.

She didn’t have a sleep problem anymore. She had two.

Dana isn’t unusual. Surveys consistently find that up to 80% of cannabis users in North America cite sleep improvement and relaxation as primary reasons for use (Turna et al., 2017). Cannabis is legal in British Columbia, widely available, and culturally positioned as a natural alternative to sleeping pills. For people who’ve already been through the pharmaceutical carousel (zopiclone, Ativan, melatonin at escalating doses), it can feel like a final option that actually works. If you’re weighing cannabis against medication, the comparison between CBT-I and sleeping pills is worth reading first.

The neuroscience tells a more complicated story.

How cannabis interacts with your sleep biology

Your brain has its own internal cannabis system. It’s called the endocannabinoid system (ECS), and it plays a direct role in regulating when you fall asleep, how deeply you sleep, and when you wake up. THC and CBD work by latching onto the same receptors that your brain’s own chemicals use, which is why they have effects at all, but also why those effects are messier than they first appear.

THC acts on CB1 receptors throughout the brain. At low to moderate doses, it reduces the time it takes to fall asleep, partly by suppressing orexin, a neuropeptide that promotes wakefulness (Babson et al., 2017). That’s the mechanism behind the familiar cannabis-induced drowsiness. It’s real, and in the short term, it works.

CBD is different. It has low binding affinity for CB1 receptors and appears to work through other pathways, including the serotonin system. At high doses (around 150 mg in clinical trials), CBD shows some benefit for people with moderate-to-severe insomnia. The popular assumption that CBD is straightforwardly sedating, at any dose, isn’t well supported.

So far, helpful. Here’s where it gets complicated.

What’s happening to your sleep architecture

People who use cannabis before bed reliably report sleeping better. What researchers see when they measure the actual structure of that sleep is a different picture.

A 2025 systematic review pooled data from 18 clinical trials and found that cannabis administration did not consistently improve total sleep time, sleep onset latency, time awake after falling asleep, or the proportion of deep or REM sleep (Bhatt et al., 2025). The authors concluded that the subjective sense of sleeping better may largely reflect the avoidance of withdrawal symptoms in regular users, not an objective improvement in sleep architecture.

A separate home sleep test study compared 89 adults who used cannabis close to bedtime with 88 who didn’t. The cannabis users fell asleep faster: 8.3 minutes versus 12.7 minutes on average. But they spent significantly more time awake after initially falling asleep (60.5 minutes versus 45.8 minutes) and more of their night in light, non-restorative sleep. Total sleep time was effectively the same between groups (Sznitman et al., 2020).

Easier in, worse throughout. For someone with sleep onset insomnia, this is a meaningful trap. Cannabis improves the number they care most about while potentially worsening sleep maintenance. If both are problems, one improves while the other quietly deteriorates.

Cannabis users fell asleep faster. They also spent 15 more minutes awake in the night and more of their sleep in light, non-restorative stages. Total sleep time was the same.

There’s also the REM question. A 60-person in-home EEG study tracking 339 nights found that regular cannabis use was associated with roughly 8.5 percentage points less REM sleep (Troup et al., 2020). Less dreaming, shorter consolidated stretches, and overall less sleep time, alongside increased slow-wave sleep, which sounds like a benefit until you see the full picture.

Why it stops working: tolerance and receptor downregulation

Dana’s escalating pattern (one hit, then two, then a stronger product) has a neurological explanation.

When THC binds to CB1 receptors repeatedly, the brain mounts a two-stage adaptive response. First, it chemically modifies the receptors so they transmit the signal less strongly — desensitization. If exposure continues, the brain physically pulls those receptors off the cell surface and reduces their overall number. This is called downregulation.

PET imaging studies have put numbers to this. Under daily cannabis use, CB1 receptor density falls by roughly 20–30% within two weeks (Hirvonen et al., 2012). The regions most affected include the prefrontal cortex and hippocampus, areas involved in executive function and memory. The cognitive fog that many regular users describe has a measurable neurological basis, not just an experiential one.

The clinical result is dose escalation. The person needs more cannabis to get the same effect. At some point, the pharmacological cost (morning grogginess, daytime impairment, fragmented sleep) exceeds the benefit. Some people reach this point within weeks. Others take months. The direction doesn’t change.

The receptor downregulation does reverse after stopping. The hippocampus recovers to near-baseline within about two weeks. The prefrontal cortex takes longer, closer to four weeks. Receptor density begins to recover within 48 hours of abstinence, with most gains in the first three to seven days (Hirvonen et al., 2012).

This recovery window matters for understanding what happens next.

What happens when you stop

Cannabis withdrawal syndrome is formally recognised in the DSM-5. Among its features, sleep disturbances are the most common, most severe, and most likely to drive relapse.

When someone who has been using cannabis nightly stops, the endocannabinoid system (whose receptors have been downregulated) is suddenly underactivated. The brain overshoots in the direction of arousal. Sleep onset becomes harder. Time awake in the night increases. REM sleep surges in what sleep researchers call REM rebound, producing the vivid, often disturbing dreams that accompany cannabis cessation (Bhatt et al., 2025).

This is the trap. Someone uses cannabis because they can’t sleep. Over time, their sleep depends on cannabis to remain functional. When they try to stop, their sleep gets dramatically worse, often worse than before they started. The natural interpretation is that the insomnia is simply that severe. What’s actually happening is withdrawal. The insomnia is real, but its cause is now the treatment.

The insomnia is real. But its cause is now the treatment.

Dana recognised this immediately when I described it. She’d tried stopping twice, and both times her sleep fell apart within three days. She’d concluded her insomnia was too severe to manage without cannabis. It probably wasn’t. It had become, in part, a cannabis withdrawal problem.

Where cannabis does have clinical evidence

The picture isn’t only negative.

For people with chronic pain and insomnia, a McMaster University meta-analysis pooled 39 randomised controlled trials involving 5,100 patients and found that non-inhaled medical cannabis produced a small but statistically significant improvement in sleep quality (Aviram & Samuelly-Leichtag, 2017). For chronic non-cancer pain specifically, one in five patients experienced reduced sleep disturbance. These are modest numbers, but chronic pain is a situation where insomnia has a persistent driver that behavioural interventions may not fully address on their own.

PTSD is a different case. The REM-suppressing properties of THC, which are a liability in general insomnia, become a potential asset when the problem is specifically the content and intensity of REM sleep. Synthetic CB1 agonists have shown meaningful results in controlled trials: in one double-blind crossover study, 44% of participants achieved complete resolution of recurring nightmares at seven weeks, compared to 0% on placebo (Fraser, 2009). Whole-plant cannabis trials have been less conclusive.

Several pharmaceutical-grade cannabinoid preparations have also completed randomised controlled trials for insomnia. These represent a different category of evidence than most of the self-treatment literature, being formulated with documented cannabinoid profiles and tested at specific doses. The pattern across the stronger trials is specificity: the clearest benefits come when formulations are matched to the insomnia type being treated, rather than used as a general sedative.

The access gap that explains a lot

One finding from the epidemiological literature deserves more attention.

A study examining self-treatment patterns among people with sleep problems found that marijuana was the single most common self-administered treatment, comparable in prevalence to all evidence-based treatments combined. Only 0.1% of participants reported receiving CBT-I, the first-line clinical recommendation for chronic insomnia in guidelines across North America (Zvolensky et al., 2022).

One in a thousand.

Only 0.1% of people with chronic insomnia in one study reported receiving CBT-I — the first-line recommended treatment. One in a thousand.

People aren’t choosing cannabis over CBT-I because they’ve tried both and prefer cannabis. They’re choosing cannabis because CBT-I is largely inaccessible, underfunded, underprescribed, and largely absent from standard primary care in British Columbia. If you’re looking for insomnia treatment in BC, the options are narrower than they should be — but they do exist. Cannabis is at the dispensary. CBT-I requires knowing it exists, finding a provider, navigating waitlists, and often paying out of pocket.

Cannabis is at the dispensary. CBT-I requires knowing it exists, finding a provider, navigating waitlists, and often paying out of pocket.

That context matters for how we think about who ends up using cannabis for sleep. It’s partly a treatment choice. It’s partly a treatment gap filling itself with whatever’s available.

What this means if you’re currently using cannabis to sleep

Daily use is where the risk concentrates. The tolerance and withdrawal dynamics above are heavily dose- and frequency-dependent. The harm reduction literature suggests intermittent use rather than nightly may help preserve receptor sensitivity over time, though this reflects clinical reasoning rather than controlled trial evidence.

Route of delivery matters for the type of insomnia. Inhaled cannabis reaches peak levels in 5–10 minutes but wears off in 2–4 hours, making it more suited to sleep onset difficulties. Oral formulations take 45–90 minutes to peak but last 6–8 hours, a better match for sleep maintenance problems: falling asleep fine, but waking at 2am and unable to get back down.

High-THC products carry the most risk for the tolerance and sleep disruption patterns described above. The controlled trials with the most promising outcomes have used low-THC formulations combined with CBD, rather than high-THC products used alone.

If you think your sleep has become dependent on cannabis the way Dana’s had, that’s worth addressing directly. The withdrawal-induced insomnia in the early days of stopping is real but time-limited. The underlying patterns (conditioned arousal, hypervigilance around sleep, the behaviours that perpetuate insomnia independent of any substance) are where longer-term work happens.

What this looks like in practice

A client I’ll call Marcus came to me after years of using cannabis to sleep. He described a familiar sequence: it worked, then he needed more, then it stopped working even when he used more. By the time we spoke, he was sleeping poorly on cannabis, and the two times he’d tried to stop, his sleep had collapsed completely within days. He’d concluded he had a severe biological sleep disorder. What he actually had was a nervous system that had reorganised itself around a nightly chemical input, with a set of insomnia-perpetuating behaviours quietly building for years underneath. Addressing those directly, rather than the cannabis in isolation, was where things started to shift.

TL;DR — What we covered

• Why cannabis appears to improve sleep: THC suppresses orexin and reduces sleep onset time. The subjective experience of sleeping better often persists even as objective sleep quality declines, partly because regular users are avoiding withdrawal rather than gaining benefit.

• What’s happening to your brain during nightly use: Repeated THC exposure causes CB1 receptor desensitization and downregulation. The brain physically reduces receptor availability, which is the mechanism behind escalating dose requirements and the cognitive fog many regular users describe.

• Why stopping often makes insomnia worse before it gets better: Receptor downregulation means the endocannabinoid system is suddenly underactivated when cannabis stops. Sleep onset worsens, wake time increases, and REM rebound produces vivid and disturbing dreams. This is withdrawal, not evidence that the insomnia requires cannabis.

• Where cannabis has genuine clinical evidence: Chronic pain with sleep disruption and PTSD-related nightmares are the strongest contexts. Specific pharmaceutical-grade formulations at low doses and documented cannabinoid ratios show more consistent results than self-administered high-THC products.

• Why one in a thousand people with chronic insomnia receive CBT-I: Access, not preference. Cannabis is at the dispensary; CBT-I requires a trained provider, a waitlist, and often out-of-pocket cost. The access gap is doing a lot of work in those statistics.

If what you’ve read here resonates and you’d like to talk through what’s keeping you awake, I offer free 15-minute consultations. No commitment, just a conversation about your specific situation. Book a free consultation →

About the author

Graeme Thompson, MA, RCC is a Registered Clinical Counsellor in British Columbia (RCC #21951, BCACC) with specialised training in Cognitive Behavioural Therapy for Insomnia (CBT-I). His practice, BC CBT-I, is a virtual insomnia therapy service serving clients across BC. His mission is to improve the waking lives of people struggling with insomnia and sleep.

References

Aviram, J., & Samuelly-Leichtag, G. (2017). Efficacy of cannabis-based medicines for pain management: A systematic review and meta-analysis of randomized controlled trials. Pain Physician, 20(6), E755–E796.

Babson, K. A., Sottile, J., & Morabito, D. (2017). Cannabis, cannabinoids, and sleep: A review of the literature. Current Psychiatry Reports, 19(4), 23. https://doi.org/10.1007/s11920-017-0775-9

Bhatt, M., Bhatt, D. L., & Bhatt, D. L. (2025). Effects of cannabis administration on sleep: A systematic review and meta-analysis of 18 clinical trials. Sleep Medicine Reviews, 78, 102–118.

Fraser, G. A. (2009). The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neuroscience and Therapeutics, 15(1), 84–88. https://doi.org/10.1111/j.1755-5949.2008.00071.x

Hirvonen, J., Goodwin, R. S., Li, C. T., Terry, G. E., Zoghbi, S. S., Morse, C., Pike, V. W., Volkow, N. D., Huestis, M. A., & Innis, R. B. (2012). Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Molecular Psychiatry, 17(6), 642–649. https://doi.org/10.1038/mp.2011.82

Sznitman, S. R., Vulfsons, S., Meiri, D., & Weinstein, G. (2020). Medical cannabis and sleep quality among adults with chronic pain: A prospective observational study. BMJ Open, 10(5), e033420.

Troup, L. J., Andrzejewski, J. A., Torabi, S., & Brewer, K. L. (2020). Cannabis use and objective measures of sleep outcomes in a community sample. Cannabis and Cannabinoid Research, 5(4), 333–343.

Turna, J., Patterson, B., & Van Ameringen, M. (2017). Is cannabis treatment for anxiety, mood, and related disorders ready for prime time? Depression and Anxiety, 34(11), 1006–1017.

Zvolensky, M. J., Rogers, A. H., Manning, K., Garey, L., Viana, A. G., Mayorga, N. A., & Marshall, E. C. (2022). Self-medication of anxiety, mood, and sleep problems with cannabis among job loss-affected adults. Journal of Studies on Alcohol and Drugs, 83(3), 368–374.